alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 32.1



CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Annual Report of Asia Premium Television Group, Inc. (the Company) on Form 10-KSB for the fiscal year ended March 31, 2005 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Jiang Qiang, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:



(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.





Date:  June 29, 2005







/s/ Qiang Jiang

Qiang Jiang

Chief Executive Officer
<TABLE> <S> <C>


<ARTICLE>                  5
<LEGEND>
</LEGEND>
<CIK>                      0001016130
<NAME>                     United Community Holdings, Inc.
<MULTIPLIER>                                                         1
<CURRENCY>                                                  US Dollars
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS                              
<FISCAL-YEAR-END>                                          DEC-31-1998
<PERIOD-START>                                             JAN-01-1998
<PERIOD-END>                                               SEP-30-1998
<EXCHANGE-RATE>                                                      1
<CASH>                                                               0
<SECURITIES>                                                         0
<RECEIVABLES>                                                        0
<ALLOWANCES>                                                         0
<INVENTORY>                                                          0
<CURRENT-ASSETS>                                                     0
<PP&E>                                                               0
<DEPRECIATION>                                                       0
<TOTAL-ASSETS>                                                       0
<CURRENT-LIABILITIES>                                                0
<BONDS>                                                              0
<PREFERRED-MANDATORY>                                                0
<PREFERRED>                                                          0
<COMMON>                                                            80
<OTHER-SE>                                                         (80)
<TOTAL-LIABILITY-AND-EQUITY>                                         0
<SALES>                                                              0
<TOTAL-REVENUES>                                                     0
<CGS>                                                                0
<TOTAL-COSTS>                                                        0
<OTHER-EXPENSES>                                                     0
<LOSS-PROVISION>                                                     0
<INTEREST-EXPENSE>                                                   0
<INCOME-PRETAX>                                                      0
<INCOME-TAX>                                                         0
<INCOME-CONTINUING>                                                  0
<DISCONTINUED>                                                       0
<EXTRAORDINARY>                                                      0
<CHANGES>                                                            0
<NET-INCOME>                                                         0
<EPS-PRIMARY>                                                     0.00
<EPS-DILUTED>                                                     0.00
        



</TABLE>
<PAGE>   1
                                                                    EXHIBIT 23.1

                       Consent of Independent Accountants

We hereby consent to the incorporation by reference in the Prospectuses
constituting part of the Registration Statements on Form S-8 (No. 33-57610,
No. 33-59050, No. 33-78094, No. 33-89828, No. 333-09383, and No. 333-29667) of
Trident Microsystems, Inc. of our report dated July 17, 1998, except for Note 10
which is as of July 24, 1998, appearing on page 24 of this Form 10-K. We also
consent to the incorporation by reference of our report on the Financial
Statement Schedules, which appears on page 40 of this Form 10-K.


PricewaterhouseCoopers LLP
San Jose, California
September 24, 1998


                                       45
<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM CONSOLIDATED
UNAUDITED  CONDENSED  FINANCIAL  STATEMENTS  FILED WITH THE COMPANY'S  MARCH 31,
2000,  QUARTERLY  REPORT ON FORM  10-QSB AND IS  QUALIFIED  IN ITS  ENTIRETY  BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<CIK>         0001016069
<NAME>       Cyberbotanical, Inc.
<MULTIPLIER>                                  1
<CURRENCY>                                    U.S. Dollars

<S>                                          <C>
<PERIOD-TYPE>                                 3-MOS
<FISCAL-YEAR-END>                             DEC-31-2000
<PERIOD-END>                                  MAR-31-2000
<EXCHANGE-RATE>                               1
<CASH>                                        411
<SECURITIES>                                  0
<RECEIVABLES>                                 0
<ALLOWANCES>                                  0
<INVENTORY>                                   0
<CURRENT-ASSETS>                              411
<PP&E>                                        0
<DEPRECIATION>                                0
<TOTAL-ASSETS>                                411
<CURRENT-LIABILITIES>                         1,010
<BONDS>                                       0
<PREFERRED-MANDATORY>                         0
<PREFERRED>                                   0
<COMMON>                                      2,042
<OTHER-SE>                                    (2,641)
<TOTAL-LIABILITY-AND-EQUITY>                  411
<SALES>                                       0
<TOTAL-REVENUES>                              0
<CGS>                                         0
<TOTAL-COSTS>                                 0
<OTHER-EXPENSES>                              959
<LOSS-PROVISION>                              0
<INTEREST-EXPENSE>                            0
<INCOME-PRETAX>                               (959)
<INCOME-TAX>                                  0
<INCOME-CONTINUING>                           (959)
<DISCONTINUED>                                0
<EXTRAORDINARY>                               0
<CHANGES>                                     0
<NET-INCOME>                                  (959)
<EPS-BASIC>                                   (0.00)
<EPS-DILUTED>                                 (0.00)


</TABLE>
UN PUBLISHED
UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 22
- 6180

ANTHONY MAURICE SMALLS , Petitioner

- Appellant ,

v. ACTING WARDEN JEFF NINES; STATE OF MARYLAND , Respondents

- Appellees

.

Appeal from the United States District Court for the District of Maryland , at Baltimore

. Catherine C. Blake, Senior District Judge. ( 1:20

- cv - 01884

- CCB )

Submitted : April 14, 2022 Decided: April 19, 2022

Before DIAZ and RUSHING, Circuit Judges, and KEENAN , Senior Circuit Judge.

Dismissed by un published per curiam opinion

. Anthony Maurice Smalls , Petitioner Pro Se.
Unpublished opinions are not binding precedent in this circuit.2 PER CURIAM: Anthony Maurice Smalls seeks to appeal the district court’s order denying on the merits his Fed. R. Civ. P. 60(b) motion s for relief from its prior order dismissing as successive his 28 U.S.C. § 2254 petition. The order is not appealable unless a circuit justice or judge issues a certificate of appealability. See 28 U.S.C. § 2253(c)(1)(A). A certificate of appealability will not issue absent “a substantial showing of the denial of a constitutional right.” 28 U.S.C. § 2253(c)(2). When the district court denies relief o n the merits, a prisoner satisfies this standard by demonstrating that reasonable jurists could find the district court’s assessment of the constitutional claims debatable or wrong. See Buck v. Davis , 137 S. Ct. 759, 773

- 74 (2017). When the district cour t denies relief on procedural grounds, the prisoner must demonstrate both that the dispositive procedural ruling is debatable and that the petition states a debatable claim of the denial of a constitutional right. Gonzalez v. Thaler , 565 U.S. 134, 140

- 41 (2012) (citing Slack v. McDaniel , 529 U.S. 473, 484 (2000)). We have independently reviewed the record and conclude that Smalls has not made the requisite showing. In his Rule 60(b) motions, Smalls challenged the validity of his state convictions and the merits of the district court’s determination that his prior petition had to be dismissed as successive . Accordingly, the motions should have been construed

as a suc cessive § 2254 petition. See Gonzalez v. Crosby , 545 U.S. 524, 531

- 32 (2005); United States v. McRae , 793 F.3d 392, 397

- 99 (4th Cir. 2015). Absent prefiling authorization from this court, the district court lacked jurisdiction to entertain Smalls’3 succes sive § 2254 petition. See 28 U.S.C. § 2244(b)(3). Accordingly, we deny a certificate of appealability and dismiss the appeal. We dispense with oral argument because the facts and legal contentions are adequately presented in the materials before this c ourt and argument would not aid the decisional process.
DISMISSED
APPLICATION
FOR SHARES

    


    
      
        
          	
                  To:

                	
                  Lone Oak Acquisition Corp.

                	
                  (the
      “Company”)

                
	 
      	
                  Cricket
      Square

                	 
      
	 
      	
                  Hutchins
      Drive

                	 
      
	 
      	
                  PO
      Box 2681

                	 
      
	 
      	
                  Grand
      Cayman, KY1-1111

                	 
      
	 
      	
                  Cayman
      Islands

                	 
      
	 
      	 
      	 
      
	
                  Attention:

                	
                  The
      Board of Directors

                	 
      


        

      

    

     

    Date: June 17, 2010

     

    I apply
for and request you to allot to me 9,999 shares with a par value of $0.001 in
the capital of the Company, and undertake to pay all calls made upon the said
shares as and when required by the directors to do so.


     

    I agree
to take the said shares subject to the Memorandum and Articles of Association of
the Company and I authorise you to enter the following name and address in the
Register of Members of the Company:

     

    
      	  	
              Name:

            	
              Berke
      Bakay

            


    

     

    
      	  	
              Address:

            	
              4975
      Preston Park Blvd., Suite# 775W, Piano TX 75093,

              United
      States of America

            


    

     

    I
designate the following telephone and facsimile numbers and e-mail address for
service of notice of all members’ meetings. Notice by telephone or facsimile to
either of the said numbers or electronic mail to the stated e-mail address will
constitute good and sufficient notice to myself and I agree to advise you of any
change in these particulars:

     

    
      	  	
              Tel:

            	
              972
      – 985 - 2190

            


    

    
      	  	
              Fax:

            	
              972-985-2101

            


    

    
      	  	
              E-mail
      address:

            	
              berkebakay@bbscapitalmanagement.com

            


    

    


    
      
        	
                Yours
      faithfully,

              	 
      
	 
      	 
      
	
                /s/ Berke Bakay

              	 
      
	
                Berke
      Bakay
```

[Federal Register Volume 82, Number 188 (Friday, September 29, 2017)]
[Notices]
[Pages 45601-45602]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20860]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute on Minority Health and Health Disparities; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the grant

[[Page 45602]]

applications, the disclosure of which would constitute a clearly 
unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Minority Health and 
Health Disparities Special Emphasis Panel; NIH Pathways to 
Independence Award (K99/R00) Review.
    Date: November 15, 2017.
    Time: 12:00 p.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Gateway Plaza, 7201 
Wisconsin Avenue, Suite 533, Bethesda, MD 20814 (Telepresence).
    Contact Person: Richard C. Palmer, DRPH, Health Scientist 
Administrator, National Institute on Minority Health and Health 
Disparities, National Institutes of Health, 6707 Democracy Blvd., 
Suite 800, Bethesda, MD 20906, (301) 451-2432, 
[email protected].

    Dated: September 25, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-20860 Filed 9-28-17; 8:45 am]
 BILLING CODE 4140-01-P
```
[Federal Register Volume 82, Number 188 (Friday, September 29, 2017)]
[Notices]
[Page 45603]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-20859]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Minority Health and Health Disparities; 
Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Minority Health and 
Health Disparities Special Emphasis Panel; ZMD1 DRI (J1) NIH Support 
for Conferences and Scientific Meetings (Parent R13).
    Date: October 23, 2017.
    Time: 12:00 p.m. to 5:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Gateway Plaza, 533, 7201 
Wisconsin Avenue, Suite 533, Bethesda, MD 20814 (Telepresence).
    Contact Person: Deborah Ismond, Ph.D., Scientific Review 
Officer, Division of Scientific Programs, National Institute on 
Minority Health and Health Disparities, National Institutes of 
Health, 7201 Wisconsin Ave., Suite 525, Bethesda, MD 20814, (301) 
594-2704, <a href="/cdn-cgi/l/email-protection#6108120c0e0f050513210c00080d4f0f08094f060e17"><span class="__cf_email__" data-cfemail="81e8f2eceeefe5e5f3c1ece0e8edafefe8e9afe6eef7">[email protected]</span></a>.


    Dated: September 25, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-20859 Filed 9-28-17; 8:45 am]
 BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>
**Exhibit 31.1****CERTIFICATION PURSUANT TO SECTION 302 OF THESAR BANES-OXLEY ACT OF 2002**I, Yan Gong, the Chief Executive Officer of Asia Premium Television Group, Inc. (the “Company”),certify that:1. I have reviewed this annual report on Form 10-K of the Company;2. Based on my knowledge, this report does not contain any untrue statement of a materialfact or omit to state a material fact necessary to make the statements made, in light of thecircumstances under which such statements were made, not misleading with respect to the periodcovered by this report;3. Based on my knowledge, the financial statements, and other financial information includedin this report, fairly present in all material respects the financial condition, results ofoperations and cash flows of the registrant as of, and for, the periods presented in this report;4. As the registrant’s certifying officer, I am responsible for establishing and maintainingDisclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d15(e)) for the registrant and I have:a) designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure that materialinformation relating to the registrant, including its consolidated subsidiaries, is madeknown to us by others within those entities, particularly during the period in whichthis report is being prepared;b) designed such internal control over financial reporting, or caused suchinternal control over financial reporting to be designed under my supervision, to providereasonable assurance regarding the reliability of financial reporting and thepreparation of financial statements for external purposes in accordance with generallyaccepted accounting principles;c) evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectiveness of thedisclosure controls and procedures, as of the end of the period covered by this report based onsuch evaluation; andd) disclosed in this report any change in the registrant’s internal control overfinancial reporting that occurred during the period covered by this report that has materiallyaffected, or is reasonably likely to materially affect, the registrant’s internal controlover financial reporting.5. As the registrant’s certifying officer, I have disclosed, based on my most recent evaluationof internal control over financial reporting, to the registrant’s auditors and the auditcommittee o registrant’s board of directors (or persons performing the equivalent function):a) all significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely to adverselyaffect the registrant’s ability to record, process, summarize and report financialinformation; andb) any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal control over financialreporting.Date:December 31, 2007                                                             /s/ Yan Gong   Yan Gong   Chief Executive Officer
IN THE SUPREME COURT OF THE STATE OF MONTANA

No. DA 22-0702

STATE OF MONTANA, 

Plaintiff and Appellee, 

v. 

JOHN DANIEL FAILS, JR

Defendant and Appellant.

ORDER

Upon consideration of Appellant’s motion for extension of time, 

and good cause appearing,

IT IS HEREBY ORDERED that Appellant is granted an extension 

of time to and including July 17, 2024, within which to prepare, file, 

and serve Appellant’s opening brief on appeal.

Electronically signed by:

Mike McGrath

Chief Justice, Montana Supreme Court

June 4 2024

06/04/2024

Case Number: DA 22-0702
AMENDMENT
No. 6


 


TO
LOAN AGREEMENT


 


This
Amendment to Loan Agreement DRICBDH0615 (the “Amendment”) is made and entered into as of January 11, 2018, by and
between Biodyne Holding SA, a Swiss corporation (the “Lender”) and Hancock Jaffe Laboratories, Inc., a Delaware corporation,
(the “Borrower”).


 


RECITALS


 


WHEREAS,
the Lender and the Borrower are party to a Loan Agreement, dated as of June 30, 2015 (the “Loan Agreement”) and
Convertible Promissory Notes with the right of transfer as determined by the Lender in accordance with Section 4 of the Loan Agreement.


 


WHEREAS,
the Lender and the Borrower desire to amend the Loan Agreement to provide for an extension of funding and repayment periods.


 


NOW,
THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of
which is hereby acknowledged, the parties hereby agree as follows:


 


Section
1.1 of the Loan Agreement is hereby amended to read as follows:


 


Section
1.1.: This Agreement sets out the terms and conditions upon which the Lender will make available to the Borrower a loan of up
to USD 2,200 ,000 (two million two hundred thousand US Dollars) in several installments through March 31, 2018.


 


Section
5 of the loan agreement is hereby amended to read as follows:


 


Section 5: REPAYMENT


 


	 	5.1.	The
    Loan shall bear interest at the rate of three per cent (3%) per annum. The interest shall be calculated from the date the
    Lender remits funds to Borrower
	 	 	 
	 	5.2.	Interest
    shall be due and payable by the Borrower to the Lender on an annual basis, the first payment to occur on March 31, 2018.
	 	 	 
	 	5.3.	The
    Borrower undertakes to repay to the Lender the Loan plus any unpaid interest accruing thereon by March 31, 2018. The Borrower
    is entitled to repay the loan and the accrued interests at any time before March 31, 2018 without penalty.


 




    	 



     


    

 


IN
WITNESS WHEREOF, the parties have executed this Amendment to the Loan Agreement as of the date first written above.


 


	 	“LENDER”
	 	 
	 	BIODYNE
    HOLDING SA
	 	 
	 	/s/
    Yury Zhivilo
	 	Yury
    Zhivilo
	 	Managing
    Director


 


	 	“BORROWER”
	 	 
	 	HANCOCK
    JAFFE LABORATORIES, INC.
	 	 
	 	/s/
    William Abbott.
	 	William
    Abbott
	 	Senior
    Vice President and
	 	Chief
    Financial Officer